Prelude Therapeutics (PRLD) Retained Earnings (2019 - 2026)

Prelude Therapeutics has reported Retained Earnings for 8 years, with the latest figure at -$693.4 million in Q1 2026.

• Quarterly Retained Earnings fell 5778816.67% year-over-year to -$693.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$693.4 million (down 5778816.67% YoY) and the FY2025 annual result came in at -$683.1 million, down 17.05% from the prior year.
• Retained Earnings retreated to -$693.4 million in Q1 2026 per PRLD's latest filing, from -$683.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at $12000.0 in Q1 2025 and troughed at -$693.4 million in Q1 2026.
• A 5-year average of -$351.3 million and a median of -$423.3 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings jumped 100.0% in 2025, then plunged 5778816.67% in 2026.
• Over 5 years, Retained Earnings stood at -$334.6 million in 2022, then sank by 36.42% to -$456.4 million in 2023, then declined by 27.86% to -$583.6 million in 2024, then declined by 17.05% to -$683.1 million in 2025, then declined by 1.52% to -$693.4 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$693.4 million, -$683.1 million, and $2000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.